Antihypertensive therapy in patients with liver diseases. Can we decrease the risk of liver fibrosis by affecting renin-angiotensin system?
https://doi.org/10.18705/1607-419X-2009-15-5-529-531
Abstract
The paper summarizes data on antihypertensive treatment in hypertensive patients with concomitant hepatic diseases when inflammation and fibrosis result in liver cytoarchitecture changes. Rennin-angiotensin-aldosterone system blockade enables to reduce tissue damage and fibrosis development regardless of blood pressure decrease. The majority of hypertensive patients requiring combination antihypertensive therapy can benefit in achieving target blood pressure faster, decreasing side effects risk, and in improving liver function. Key words: hypertension, liver diseases, rennin-angiotensin-aldosterone system blockade.
About the Authors
O. M. Drapkina
I.M. Sechenov Moscow Medical Academy
Russian Federation
Russian Federation
Y. V. Dubolazova
I.M. Sechenov Moscow Medical Academy
Russian Federation
Russian Federation
References
1. I Шальнова С.А., Марцевич С.Ю., Деев Л.Д. и др. Артериальная гипертензия в России: исследование «ПРОЛОГ» как способ доказательства возможностей современной терапии // Рацион. фармакотерапия в кардиологии. 2005. - № 1.
2. Lubel J.S., Herath СВ., Burrcll L.M., Angus P.W. Liver disease and the renin-angiotensin system: recent discoveries and clinical implications / J. Gastroenterol. Hepatol. 2008. - Vol. 23. - № 9. - P. 1327-1338.
3. Shcn X.X., Xiao H.D., Li P. et al. New insights into the role of angiotensin-converting enzyme obtained from the analysis of genetically modified mice // J. Mol. Med. - 2008. Vol. 86, - № 6. - P. 679-684.
4. Casillas-Ramirez A., Amine-Zaouali M., Massip-Salccdo M. et al. Inhibition of angiotensin II action protects rat steatotic livers against ischcmia-reperl'usion injury. Crit. Care Med. 2008. - Vol. 36. - №4. - P. 1256-1266.
5. Toblli J.L., Muftoz M.C., Cao G. et al. AC'H inhibition and All receptor blockade prevent fatty liver and fibrosis in obese Zucker rats // Obesity (Silver Spring). - 2008. - Vol. 16. № 4. - P. 770-776.
6. Дранкина О.М., Тутпов Д.А. Особенности лечения артериальной гипертонии у больных с заболеваниями печени // Рос. мед. вести. 2008. - Т. XIII. - № 3. - С. 43-48.
7. Рекомендации но лечению артериальной гипертонии Европейского Общества Гипертонии и Европейского общества Кардиологов 2007 г.
8. Gere V., Begovic В., Vehabovic M. et al. Effects of fixed combination of lisinopril plus hydrochlorothiazide on regression of left ventricular hypertrophy in patients with essential hypertension: an opened, multi-centre, prospective clinical trial // Bosn. J. Basic Med. Sci. - 2008. - Vol. 8, №3. - P. 214-219.
9. Gere V., Begovic В., Vehabovic M. et al. Fixed combination lisinopril plus hydrochlorothiazide in the treatment of essential arterial hypertension: an opened, multi-centre, prospective clinical trial // Bosn. J. Basic Med. Sci. 2007. - Vol. 7, № 4. - P. 377-382.
Review
For citations:
Drapkina O.M., Dubolazova Y.V. Antihypertensive therapy in patients with liver diseases. Can we decrease the risk of liver fibrosis by affecting renin-angiotensin system? "Arterial’naya Gipertenziya" ("Arterial Hypertension"). 2009;15(5):529-531. (In Russ.) https://doi.org/10.18705/1607-419X-2009-15-5-529-531
Views:
962
Email this article 